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AUC Area under the concentration-time curve 
BCRP Breast cancer resistance protein 
CsA Cyclosporine A 
CYP Cytochrome p450 
DDI Drug-drug interaction 
DMEM Dulbecc's modified Eagle's medium 
E1S Estrone 3-sulfate 
E2G [3H]Estradiol-17β-glucuronide 
EMA European Medicines Agency 
ESI Electrospray ionization 
FDA U.S. Food and Drug Administration 
HEK293 Human embryonic kidney cells 293 
ICH 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use 
KH Krebs–Henseleit 
LC Liquid chromatography 
MHLW Japanease Ministry of Health, Labour and Welfare 
MRP Multidrug resistance-associated protein 
MS Mass spectrometry 
NME New molecular entity 
OATP Organic anion transporting polypeptide 
PDGFR Platelet-derived growth factor receptor 
P-gp P-glycoprotein 
UGT Uridine diphosphate glucuronosyltransferase 
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Ki 1.1 CsA rifampicin DDI
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vivo DDI OATP
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Kajosaari et al., 2005; Amundsen et al., 2012 rifampicin
CYP3A Williamson et al., 2013
Strolin Benedetti and Philippe, 1994 pravastatin
CsA rifampicin Cyp3a
Cyp3a midazolam pravastatin  
Oatp in vivo DDI
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2-2-1. CsA rifampicin pravastatin  
CsA 0.1 0.5 1 3 5 mg/kg rifampicin 10 mg/kg
pravastatin midazolam Pravastatin
CsA AUC 1 3 5 mg/kg CsA
Fig. 1A, Table 1 Cyp3a midazolam
CsA Fig. 1B, Table 1 rifampicin
1 pravastatin pravastatin AUC AUC
Fig. 1A, Table 1 10 mg/kg 25 mg/kg rifampicin 5
pravastatin pravastatin AUC
Fig. 1C, Table 2 midazolam rifampicin
Fig. 1D, Table 2 Table 1 CL/F pravastatin
5 CsA Fig. 2 1
Ki,invivo 0.0105 nM  
CsA Oatp in vivo CsA 1 3 7
pravastatin Paravastatin AUC CsA 1 3
Fig.3, Table 3 pravastatin AUC CsA 1 3 7 4.63 3.03
1.36 pravastatin CL/F CsA
Ki,invivo 0.0105 nM 1
Fig. 2  
 





KH buffer Pravastatin CsA rifampicin
Fig. 4A and B 2 CsA rifampicin IC50
0.0843 ± 0.0268 0.934 ± 0.195 μM CsA fu,p
0.0023 DDI / fu,p 0.01
fu,p 0.01 R0’ CsA 1
pravastatin R0’ 0.0023 0.01 R0’
1.00-1.05 AUC 1.88–4.19 Table 1 CsA
1 3 7 pravastatin R0’ 1.00-1.06 AUC
1.36–4.63 Table 3 rifampicin 1 pravavastatin
R0’ 1.02 AUC 1.07 Table 1
rifampicin 5 pravastatin R0’ 2.09–5.65







Fig. 4A and B 2
IC50 CsA
rifampicin IC50 10.5 ± 5.0 27.8 ± 6.0 μM
CsA rifampicin IC50 0.0482 ± 0.0269




2-2-4. CsA Oatp  
CsA M1 pravastatin
Pravastatin M1 Fig. 
4C IC50 0.158 ± 0.028 μM M1 CsA Oatp
P450 ABT CsA
pravastatin ABT CsA ABT
Fig.5, Table 4 CsA pravastatin
CsA CsA M1 R0’




Fig. 1. Plasma concentration-time profiles of pravastatin (A, C) and midazolam (B, D) after their 
concomitant oral administration with or without CsA or rifampicin given as a bolus intravenous 
administration in male SD rats. 
(A, B) Vehicle alone (○), 0.1 (△), 0.5 (□), 1 (◇), 3 (▲) and 5 mg/kg (■) CsA or 10 mg/kg (◆) 
rifampicin was intravenously administered, and, after 1 day, mixture of pravastatin (30 mg/kg, A) and 
midazolam (10 mg/kg, B) was orally administered. (C, D) Vehicle alone (○), 10 (▲) and 25 (■) mg/kg 
rifampicin was intravenously administered, and, after 5 min, mixture of pravastatin (C) and midazolam 






Fig. 2. Relationship between unbound CsA concentration in plasma and oral clearance (CL/F) 
of pravastatin in CsA-pretreated rats. 
The CL/F of pravastatin (○) at 1 day after CsA-pretreatment were obtained from the data shown in 
Fig. 1A and normalized by that in vehicle treated rats. The normalized CL/F was fitted to Eq. 1, 
yielding fitted line shown as dashed line and Ki,in vivo of 0.0105 ± 0.0086 nM. The CL/F of pravastatin 
at 1 (◇), 3 (□) and 7 (△) day after CsA-pretreatment were obtained from data shown in Fig. 3, 
normalized by that in control rats and also plotted. The CL/F of pravastatin orally administered at 1 
day after CsA-pretreatment in rats receiving intravenous administration of CYP inhibitor ABT (◆) 
was obtained from data shown in Fig. 5, normalized by that in CsA non-treated rats with ABT 
pretreatment and also plotted. Plasma concentration of CsA was measured at 5 min after oral 
administration of pravastatin in all groups, and unbound CsA concentration was then calculated by 
multiplying total plasma concentration of CsA with its unbound fraction (0.0023). Each point 







Fig. 3. Plasma concentration-time profiles of pravastatin after oral administration with or 
without CsA given as an intravenous bolus dose. 
Rats received CsA (5 mg/kg,  ) or vehicle ( ), and pravastatin (30 mg/kg) was orally administered 










Fig. 4. Inhibition by CsA (A), RIF (B) and M1 (C) of the uptake of pravastatin in cryopreserved 
rat hepatocytes. 
Uptake of pravastatin was measured in KH buffer (○) and rat serum (■, □) conditions, and normalized 
by control value. Concentration of total (○, ■) and unbound (□) forms of CsA (A) and RIF (B) in the 
medium were experimentally measured and shown in abscissa. Dashed, thin and thick lines represent 
fitted lines based on Eq. 2 for the inhibition curves based on total concentration in KH buffer, and 
unbound or total concentration of inhibitor in rat serum, respectively. Each point represents the mean 






Fig. 5. Plasma concentration-time profiles of pravastatin after oral administration with or 
without CsA given as an intravenous bolus dose. 
Rats received intravenous administration of ABT (50 mg/kg; □, ◇) in panel (A) or saline (○, △) in 
panel (B). After 16 h, CsA (0.5 mg/kg; ◇, △) or vehicle alone (□, ○) was intravenously administered. 
Pravastatin (30 mg/kg) was then orally administered at 1 day after the CsA or vehicle administration. 






Pharmacokinetic parameters of pravastatin (30 mg/kg) and midazolam (10 mg/kg) at 1 day after intravenous administration of CsA (0.1, 0.5, 1, 3 and 5 mg/kg) 
and rifampicin (10 mg/kg)a 
  Dose (mg/kg) 




nmol/L h mL/min/kg nmolh/L nmol/L 
Pravastatin 
Control   146 ± 49 0.250 ± 0.000 5.67 ± 0.73 200 ± 24 -        1 
CsA 0.1 274 ± 68 0.333 ± 0.144 2.94 ± 0.81 398 ± 94 1.95 7.01 ± 0.72 1.00(1.00) 
  0.5 268 ± 56 0.250 ± 0.000 3.03 ± 0.60 381 ± 77 1.88 35.9 ± 7.3 1.00(1.00) 
  1 433 ± 141* 0.250 ± 0.000 1.91 ± 0.71** 662 ± 311** 3.10 67.1 ± 29.8 1.00(1.01) 
  3 533 ± 114** 0.333 ± 0.144 1.38 ± 0.42*** 855 ± 224*** 4.19 219 ± 29 1.01(1.03) 
  5 552 ± 204** 0.250 ± 0.000 1.79 ± 0.82** 721 ± 326* 3.37 399 ± 63 1.01(1.05) 
Rifampicin 10 108 ± 48 0.500 ± 0.433 5.85 ± 3.36 233 ± 113 1.07 187 ± 120 1.02 
Midazolam 
Control   632 ± 257 0.194 ± 0.096 8.67 ± 4.01 727 ± 339          
CsA 0.1 831 ± 355 0.333 ± 0.144 6.55 ± 1.47 945 ± 282 1.37   -   - 
  0.5 705 ± 331 0.271 ± 0.172 7.80 ± 2.98 773 ± 414 1.05   -   - 
  1 606 ± 234 0.250 ± 0.000 8.00 ± 1.72 660 ± 135 0.96   -   - 
  3 717 ± 138 0.333 ± 0.144 5.50 ± 0.31 935 ± 50 1.39   -   - 
  5 861 ± 447 0.194 ± 0.096 7.90 ± 4.65 778 ± 341 1.06   -   - 




*Significantly different from control (p < 0.05) 
**Significantly different from control (p < 0.01) 
***Significantly different from control (p < 0.001) 
aMean ± S.D. in 3 to 4 rats.  
bEstimated as ratio of geometric mean of AUC in CsA- or rifampicin-treated rats to that in vehicle-treated (control) rats. 
cPlasma concentration of CsA or rifampicin at 5 min after oral administration of pravastatin. 






Pharmacokinetic parameters of pravastatin (30 mg/kg) and midazolam (10 mg/kg) at 5 min after intravenous administration of rifampicin (10 and 25 
mg/kg)a 
  Dose (mg/kg) 




nmol/L h mL/min/kg nmolh/L µmol/L 
Pravastatin 
Control   80.8 ± 34.3 0.667 ± 0.289 7.21 ± 1.09 158 ± 26  1     
Rifampicin 10 380 ± 65** 1.08 ± 0.88 1.51 ± 0.87* 910 ± 464* 5.29 9.90 2.09 
  25 1090 ± 501*** 0.333 ± 0.144 0.420 ± 0.110* 2760 ± 686* 17.2 31.0 5.65 
Midazolam 
Control   428 ± 36 0.500 ± 0.000 777 ± 194 702 ± 174  1   
Rifampicin 10 350 ± 85 1.00 ± 0.87 849 ± 493 734 ± 347 0.71 - - 
 25 436 ± 42 0.417 ± 0.144 594 ± 187 936 ± 359 1.30 - - 
*Significantly different from control (p < 0.05) 
**Significantly different from control (p < 0.01) 
***Significantly different from control (p < 0.001) 
aMean ± S.D. in 3 rats. 
bEstimated as ratio of geometric mean of AUC in rifampicin-treated rats to that in vehicle-treated (control) rats. 
cPlasma concentration of rifampicin at 5 min after oral administration of pravastatin. 




Pharmacokinetic parameters of pravastatin (30 mg/kg) at 1, 3, and 7 day after intravenous 
administration of CsA (5 mg/kg)a 
    Cmax Tmax CL/F (×103) Ipb AUC 
    nmol/L h mL/min/kg nmol/L nmol·h/L 
Day 1 Control 136 ± 101 0.436 ± 0.125 8.42 ± 4.80       182 ± 121 
  CsA 557 ± 258* 0.360 ± 0.129 1.80 ± 0.97 498 ± 109 787 ± 404* 
  R0’ valuec)                     1.01 (1.06c) 
  AUC ratiod)                     4.63 
                                  
Day 3 Control 93.2 ± 25.7 0.313 ± 0.125 7.71 ± 2.53       158 ± 67 
  CsA 398 ± 70*** 0.250 ± 0.000 2.14 ± 0.40* 266 ± 98 537 ± 109** 
  R0’ valuec)                     1.01 (1.03c) 
  AUC ratiod)                     3.03 
                                  
Day 7 Control 89.6 ± 40.7 0.333 ± 0.144 12.8 ± 7.2       113 ± 76 
  CsA 111 ± 47 0.333 ± 0.144 8.04 ± 2.11 3.69 ± 0.80 157 ± 60 
  R0’ valuec                     1.00 (1.00c) 
  AUC ratiod                     1.36 
*Significantly different from control (p < 0.05) 
**Significantly different from control (p < 0.01) 
aMean ± S.D. in 3 to 4 rats. 
bPlasma concentration of CsA at 5 min after oral administration of pravastatin. 
cEstimated by Eq. 5. R0’ values in parenthesis were calculated assuming that the unbound fraction of 
CsA was 0.01. 






Pharmacokinetic parameters of pravastatin (30 mg/kg) in rats at 1 day after intravenous administration of CsA or vehicle alone in ABT-pretreated and ABT 
non-treated ratsa 
  
Cmax Tmax CL/F (×103) AUC CsAb M1b 
AUC ratioc 
R0’-valued 
nmol/L h mL/min/kg nmol·h/L nmol/L nmol/L CsA M1 
Control 55.8 ± 17.2 0.375 ± 0.144 16.7 ± 6.7 76.6 ± 33.7              1 1 
CsA 77.8 ± 38.7 0.438 ± 0.125 8.47 ± 4.41 177 ± 124 27.6 ± 3.40 0.693 ± 0.218 2.31 1.00 (1.00d) 1.00 
ABT 91.0 ± 46.3 0.438 ± 0.125 8.46 ± 4.35 163 ± 81.3              1 1 
CsA+ABT 215 ± 110 0.438 ± 0.125 3.39 ± 1.77 409 ± 205 50.4 ± 4.80 1.09 ± 0.520 2.31 1.00 (1.01d) 1.00 
aMean ± S.D. in 3 to 4 rats. Dose of CsA and ABT were 0.5 and 50 mg/kg, respectively. 
bPlasma concentration of CsA or M1 at 5 min after oral administration of pravastatin. 
cEstimated as ratio of geometric mean of AUC in CsA to control group and that in CsA+ABT to ABT group. 
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3-2-1. Pazopanib OATP1B1  
Pazopanib OATP1B1  OATP
CsA rifampicin HEK293/OATP1B1 pazopanib
1 60  [3H]E1S [3H]E2G
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Fig. 1A, B, Table 1 CsA
IC50  IC50 pazopanib 5-60
Fig. 1C, Table 1  
rifampicin IC50
IC50 Fig. 1D, Table 1 Pazopanib
5 60  
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3-2-2. Pazopanib OATP1B1  
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transport buffer pre  [3H]E1S
pazopanib  Pre + Co  Co
Fig. 2A CsA  Pre [3H]E1S Pre+Co
 Co Fig. 2B  Pre
[3H]E1S  Pre+Co Co Fig. 2C  
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Table 2  
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OATP1B1 E1S Km Vmax  
Fig. 4, Table 3  CsA OATP1B1
E1S Km Vmax CsA Fig. 4, Table 3
  Km Vmax
Fig. 4, Table 3  
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OATP1B1  CsA trans-inhibition 
OATP1B1 Shitara et al., 
2017; Sprowl et al., 2016  pazopanib CsA OATP1B1
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 29 
pazopanib CsA p  HEK293/OATP1B1
0.295 0.178  
 
3-2-5. Pazopanib OATP1B1 DDI   
Pazopanib DDI Teble 4 5
IC50 0.314 μM






Fig. 1. Uptake activity of OATP1B1 after preincubation with pazopanib, CsA, and rifampicin. 
HEK293/OATP1B1 cells were preincubated with various concentrations of pazopanib (A, B), CsA 
(C), and rifampicin (D) for a designated time periods (1–60 min). After the preincubation, the medium 
was removed, and the cells were further incubated with the buffer including each inhibitor and [3H]E1S 
(A, C, D) or [3H]E2G (B) for 0.5 min. Cells were washed, and radioactivity associated was determined. 
Uptake of [3H]E1S and [3H]E2G in HEK293/mock cells was under detection limit. Solid and dashed 
lines represent inhibition curves under the condition without preincubation (both inhibitors and 
substrate were simultaneously added) and with preincubation for 30 min, respectively. Data are shown 










Fig. 2. Uptake of [3H]E1S by OATP1B1 under the condition of coincubation (Co), 
pre+coincubation (Pre +Co), and preincubation alone (Pre) with inhibitors. 
Under the coincubation condition (Co, closed circles), HEK293/OATP1B1 cells were preincubated 
without inhibitor for 30 min, and then incubated with [3H]E1S and indicated concentration of 
pazopanib (A), CsA (B), and rifampicin (C) for 0.5 min. Under the pre+coincubation condition 
(Pre+Co, open circles), the cells were preincubated with pazopanib, CsA, and rifampicin for 30 min, 
and the medium was replaced with the buffer containing each compound and [3H]E1S, followed by 
further incubation for 0.5 min. Under the preincubation condition (Pre, open triangles), the cells was 








Fig. 3. Recovery of OATP1B1 activity after preincubation with pazopanib, CsA, and rifampicin. 
In panel (A), HEK293/OATP1B1 cells were preincubated with pazopanib (10 μM, ○), CsA (0.3 μM, 
△), and rifampicin (100 μM, □ ) for 30 min, washed, and further incubated in the absence of each 
inhibitor for the designated periods. In panel (B), HEK293/OATP1B1 cells were preincubated with 
designated concentration of pazopanib for 30 min, washed, and further incubated in the absence of 
pazopanib for the designated periods. Then, the medium was replaced with the buffer containing 
[3H]E1S and further incubated for 0.5 min. Cells were washed, and radioactivity associated was 
determined. Data were normalized by the control value obtained without the inhibitor and shown as 







Fig. 4. Eadie-hofstee plot for OATP1B1-mediated uptake of E1S after preincubation with 
pazopanib, CsA, and rifampicin. 
HEK293/OATP1B1 cells were preincubation with vehicle (○), 1 μM pazopanib (◇) , 0.1 μM CsA (□), 
and 3 μM rifampicin (△) for 30 min, followed by washing the cells and further incubation with [3H]E1S 
in the presence of various concentrations of unlabeled E1S, but not the inhibitor for 0.5 min. Cells 








Fig. 5. Interaction between pazopanib and CsA in their inhibitory effect on uptake of [3H]E1S in 
HEK293/OATP1B1 cells (A) and human hepatocytes (B). 
HEK293/OATP1B1 cells (A) and human hepatocytes (B) were preincubation with a mixture of 
pazopanib and CsA at the designated concentration, followed by washing the cells and further 
incubation with [3H]E1S for 0.5 min. Cells were washed, and radioactivity associated was determined. 
Data were normalized by the control value obtained without the inhibitor and shown as mean ± S.E. 










 IC50 value (μM)a 
Inhibitors Pazopanib Pazopanib CsA Rifampicin 
Substrates [3H]E1S [3H]E2G [3H]E1S [3H]E1S 
0  1.42 ± 0.23  13.5 ± 6.0 0.383 ± 0.128 1.50 ± 0.13 
1  0.594 ± 0.030  7.25 ± 0.53 0.0755 ± 0.0234 1.67 ± 0.26 
5  0.314 ± 0.028  2.27 ± 0.74 0.0594 ± 0.0167 1.19 ± 0.07 
30  0.374 ± 0.074  2.58 ± 0.77 0.0692 ± 0.0160 2.51 ± 0.10 
60  0.530 ± 0.022  2.03 ± 0.71 0.0759 ± 0.0154 2.87 ± 0.45 
a IC50 values were estimated based on the data shown in Fig. 1 by a nonlinear least-squares regression analysis (parameter estimate ± 






krecovery values after preincubation with pazopanib, CsA, and rifampicin 
Inhibitors Concentration (μM) krecovery (h-1)a 
Pazopanib 0.1 >3.31 
  0.3 >6.26 
  1 6.99 
  3 7.16 
  10 5.62-9.46b 
CsA 0.3 0.546 
Rifampicin 100 >20.4 
a The krecovery was calculated by replotting the data shown in Fig. 3 into sigma-minus plot in logarithmic 
scale, followed by linear regression analysis. 






Effect of preincubation with pazopanib, CsA, and rifampicin on kinetic parameters for OATP1B1-
mediated uptake of [3H]E1Sa 
  Vmax Km PSdif 
  pmol/min/mg protein nM μL/min/mg protein 
Control 15.0 ± 2.7 38.9 ± 13.5 15.4 ± 1.9 
Pazopanib 11.7 ± 2.8 64.4 ± 25.7 7.23 ± 1.49 
CsA 9.33 ± 1.99 67.8 ± 22.9 9.66 ± 1.28 
Rifampicin 5.56 ± 0.63 21.7 ± 3.83 10.4 ± 0.8 






Calculation of R1’ value for pazopanib 
Pharmacokinetic parameters Units References 
Iin 92.8 μM Votrient Tablets, 2009 
ka 0.00968 min-1 Votrient Tablets, 2009 
FaFg 0.247   Votrient Tablets, 2009 
Dose 30.5 μmol/kg Votrient Tablets, 2009 
Qh 97 L/h/70kg Yang et al., 2007 
RB 0.59   Votrient Tablets, 2009 
IC50 0.314 μM Table 1 
Iin,max 95.3 μM Calculated by Eq. 7 
fu,p 0.00018   Obtained in the present study 






Summary of pazopanib-induced drug interactions 




Midazolam 3 mg 1.32 1.29 CYP3A   Goh et al., 2010 
Dextromethorphan 30 mg 1.33–1.64 - CYP2D6   Goh et al., 2010 
Caffeine 200 mg 1.00 0.98 CYP1A2   Goh et al., 2010 
Warfarin 10 mg 0.82 1.03 CYP2C9   Goh et al., 2010 
Omeprazole 40 mg 0.81 0.84 CYP2C19   Goh et al., 2010 
Docetaxel 50 mg/m2 1.50 1.47 OATP1B1, CYP3A   Hamberg et al., 2015 
Paclitaxel 80 mg/m2 1.26 - CYP2C8, CYP3A   Tan et al., 2010 
Simvastatina - N.D. N.D. OATP1B1, CYP3A ALT  3 Odds ratio (2.2)b Xu et al., 2012 
Atorvastatina - N.D. N.D. OATP1B1, CYP3A ALT  3 Odds ratio (1.3)b Xu et al., 2012 
SN-38 120 mg/m2 1.89 - OATP1B1, UGT1A1   Bennouna et al., 2015 
 a Dose were not described in the report. 







Pazopanib in vitro OATP1B1 OATP1B3
OATP1B1
Goh et al., 2010; Tan et al., 2010; Xu et al., 2012; Bennouna et al., 2015; Hamberg et al., 




pazopanib transport buffer [3H]E1S
Fig. 1A
pazopanib IC50 5 60








HEK293/OATP1B1 pazopanib CsA rifampicin 30
[3H]E1S transport buffer Pre
[3H]E1S
Fig. 2 Shitara CsA




Ellawatty et al., 2018 pazopanib IC50





Sprowl et al., 2016 C OATP1B1 1B3
Hong et al., 2015; Powell et al., 2014 pazopanib
pre OATP1B1 OATP1B1
OATP1B1  
HEK293/OATP1B1 pazopanib OATP1B1 10
CsA Fig. 3
pazopanib CsA OATP1B1
pazopanib CsA rifampicin OATP1B1
E1S
Pazopanib OATP1B1 E1S Km Vmax
Table 3 CsA rifampicin Km
Vmax rifampicin Km







DDI [3H]E2G in vitro
Izumi et al., 2015 pazopanib
OATP1B1  [3H]E1S [3H]E2G  [3H]E2G
pazopanib IC50 [3H]E1S IC50 Table 1
[3H]E2G OATP1B1 IC50 OATP1B1
IC50 OATP1B1
 
rifampicin preincubation OATP1B1 Fig. 1D
Shitara [3H]E1S rifampicin OATP1B1





OATP1B1 docetaxel SN-38 AUC pazopanib
1.5–2 Bennouna et al., 2015; Hamberg et al., 
2015 pazopanib OATP1B1 DDI
IC50 0.314 μM, Table1 R1’ R1’ 1.09
Table 4 pazopanib OATP1B1 DDI
Pazopanib P450
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4
Goh et al., 2010 docetaxel OATP1B1
-1187G>A, c.388G>A, c.521>C CYP3A4/5*2
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Yamada et al., 2014; Barker et al., 2009 pazopanib docetaxel
AUC OATP1B1 CYP3A4 SN-38
SN-38 UGT1A1
Fujita et al., 2014 pazopanib UGT1A1 pazopanib
Xu et al., 2010 pazopanib
SN-38 AUC UGT1A1 Iwase
Iwase et al., 2019 OATP1B1
pazpoanib docetaxel SN-38 DDI
pazopanib Ki
OATP1B1 DDI Xu pazopanib
ALT OATP1B1 simvastatin
Xu et al., 2012 simvastatin









4 OATP1B1  
1  









CsA DDI OATP1B1 E1S
E2G DDI atorvastatin pitavastatin rosuvastatin
OATP1B1 Izumi et al., 2015
OATP1B1
R R0 R1 R2 R3 OATP1B1 100% R’






OATP1B1 asunaprevir regorafenib nilotinib asunaprevir










Table 1  
 
4-2-2. CsA OATP1B1  
HEK293/OATP1B1 CsA transport 
buffer OATP1B1 CsA
OATP1B1 CsA
Fig. 2 [3H]E1S [3H]E2G pitavastatin rosuvastatin
OATP1B1 20 1
Fig. 2 A, B, D and E atorvastatin
OATP1B1 3 Fig. 2C
20
[3H]E1S [3H]E2G pitavastatin rosuvastatin kobs,app 0-
20 OATP1B1 kobs,app
CsA Fig. 3 kinact KI 4 Table 1  
 




OATP1B1 0.3 μM CsA
[3H]E1S [3H]E2G atorvastatin pitavastatin rosuvastatin




4-2-4. R DDI  
CsA fu,p in house 0.0107
OATP1B1 f
Kunze et al., 2014; Izumi et al., 2018; Zhang et al., 2019 CsA
Table 2 5 6 R0
AUC Table 1
IC50 R1 AUC Table 1
8 R2 11 R3 R1
AUC OATP1B1 DDI
f 1 R’ R1’ R1
AUC R2’ R3’ R2 R3
AUC Table 1  
 
4-2-5. CsA OATP1B1 DDI  
CsA simeprevir asunaprevir ritonavir
OATP




OATP1B1 Sprowl et al., 2016
30 [3H]E1S
Fig. 5 OATP1B1 asunaprevir
regorafenib nilotinib pazopanib CsA
OATP1B1 DDI
Fig. 6–8 Table 3 4
Asunaprevir OATP1B1
30 OATP1B1
Table 4 regorafenib nilotinib
10 μM [3H]E1S
25 17%  
R Table2 3 Regorafeni
nilotinib R0’ 1 R1’ R2’ R3’ 1.2–1.3 pazopanib
R2’ R3’ 2 Asunaprevir OATP1B1
rosuvastatin DDI rosuvastatin OATP1B1 R
R0 R1 AUC R2 R3







Fig. 1. Inhibition of OATP1B1-mediated uptake of [3H]E1S (A), [3H]E2G (B), atorvastatin (C), 
pitavastatin (D) and rosuvastatin (E) after preincubation with CsA. 
The cells were washed with transport buffer prewarmed at 37°C, then pretreated for 5 min with the 
transport buffer without substrates or inhibitors. The medium was then replaced with the transport 
buffer containing inhibitors at the various concentrations of CsA, and cells were further preincubated 
for 0 or 30 min at 37°C. After the preincubation, the transport buffer containing inhibitors was removed, 
and the reaction was then started by applying prewarmed fresh transport buffer containing [3H]E1S, 
[3H]E2G, atorvastatin (0.3 μM), pitavastatin (0.5 μM) or rosuvastatin (3 μM) and the inhibitors to the 
cells. At 0.5 min ([3H]E1S and [3H]E2G) or 1 min (atorvastatin, pitavastatin, and rosuvastatin), the 
reaction solution was removed by aspiration, and cells were washed with ice-cold transport buffer. 
OATP1B1-mediated uptake was obtained by subtracting the uptake in HEK293/mock cells from that 
in HEK293/OATP1B1 cells. Data are shown as percentage mean uptake volume values ± S.E. (n = 3-







Fig. 2. Inactivation of OATP1B1-mediated transport of [3H]E1S (A), [3H]E2G (B), atorvastatin 
(C), pitavastatin (D) and rosuvastatin (E) after preincubation with CsA 
HEK293/OATP1B1 cells were preincubated with CsA at 0 ( ), 0.02 (△), 0.05 (□), 0.1 (●), 0.2 (▲), 
and 0.5 μM (■) for [3H]E1S and [3H]E2G, 0 ( ), 0.005 (△), 0.01(□), 0.02 (●), 0.05 (▲), and 0.1 μM 
(■) for atorvastatin, pitavastatin, and rosuvastatin for designated period. After preincubation, the cells 
were once washed with prewarmed transport buffer and incubated with each substrate. At 0.5 ([3H]E1S 
and [3H]E2G) or 1 min (atorvastatin, pitavastatin, and rosuvastatin), the reaction solution was aspirated, 
and the cells were twice washed with ice-cold transport buffer, followed by determination of their 
uptake. Uptake values are represented as the percentage of the activity obtained in the vehicle control 








Fig. 3. Observed kobs,app of OATP1B1-mediated transport of [3H]E1S (A), [3H]E2G (B), 
atorvastatin (C), pitavastatin (D) and rosuvastatin (E) versus CsA concentration. 
The kobs,app values were determined as the negative slopes of the natural logarithm (0 to 20 sec for 
[3H]E1S, [3H]E2G, pitavastatin, and rosuvastatin; 0 to 3 min for atorvastatin) shown in Fig. 2. Solid 
lines represent the fitting curves of the observed kobs,app versus CsA concentration by nonlinear 






Fig. 4. Recovery of OATP1B1 activity after preincubation with CsA. 
HEK293/OATP1B1 cells were preincubated with culture medium containing CsA (0.3 μM) for 30 min. 
The medium was replaced with fresh culture medium and further incubated in the absence of CsA for 
designated periods. The cells were then washed with prewarmed transport buffer once, and the 
transport buffer, including [3H]E1S ( ), [3H]E2G ( ), atorvastatin ( ), pitavastatin ( ), and 
rosuvastatin ( ), was added, followed by determination of their uptake. Data are normalized with the 






Fig. 5. Screening of preincubation dependent OATP1B1 inhibitors. 
HEK293/OATP1B1 and HEK293/mock cells was first preincubated with each compound at 1 µM for 
30 min (closed column) or subjected to no preincubation (open column). Cells were then incubated 
with [3H]E1S and each compound for 0.5 min, followed by determination of OATP1B1-mediated 







Fig. 6. OATP1B1 activity after preincubation with regorafenib, nilotinib, and asunaprevir. 
HEK293/OATP1B1 cells were preincubated with various concentrations of regorafenib, nilotinib, and 
asunaprevir for designated time periods (1 60 min). After the preincubation, the medium was replaced 
with the buffer containing each compound and [3H]E1S, followed by further incubation for 0.5 min 
and determination of radioactivity associated. Solid and dashed lines represent inhibition curves under 
the condition without (both inhibitors and substrate were simultaneously added) or with preincubation 
for 60 min, respectively. Data were shown as mean values ± S.E. (n = 3-6) and compared with those 






Fig. 7. Observed kobs,app values for OATP1B1-mediated transport of [3H]E1S versus OATP1B1 
inhibitor concentration. 
HEK293/OATP1B1 cells were preincubated with regorafenib (A), nilotinib (B), pazopanib (C), and 
asunaprevir (D) for designed period. After the preincubation, the cells were washed with prewarmed 
transport buffer and incubated with [3H]E1S. At 0.5 min, the cells were washed, followed by 
determination of the associated radioactivity. The kobs,app values were determined as the negative slopes 
of the natural logarithm. Solid lines represent the fitting curves of the observed kobs,app versus each 








Fig. 8. Recovery of OATP1B1 activity after preincubation with OATP1B1 inhibitors. 
HEK293/OATP1B1 cells were preincubated with regorafenib (10 μM, ), nilotinib (1 μM, △), 
pazopanib (10 μM, □), and asunaprevir (5 μM, ◇) for 60 min, washed, and further incubated in culture 
medium without each inhibitor for the designated periods. Then, the medium was replaced with the 
buffer containing [3H]E1S, and cells were further incubated for 0.5 min, followed by determination of 
radioactivity associated. Data were normalized by the control value obtained without the inhibitor and 
are shown as mean ± S.E. (n = 3). Similar data for pazopanib have previously been obtained (Taguchi 







Kinetic parameters for inhibition, inactivation, and recovery of OATP1B1 activity, and estimation of DDIs potential of CsA 
Substrates 
IC50 (μM) kinactc kIc kobsd krecoverye fu,p Iu,inlet,maxf f g R0 R1 R2 R3 
Observed 
AUC 
ratio Pre(-)a Pre(+)b min-1 μM min-1 min-1 (CsA) μM (R1')g (R0')g (R1')g (R2')g (R3')g 
E1S 0.169 0.0354 2.47 0.145 0.369 0.0122 
0.0107 0.0117 
0.77 1.11 1.48 3.93 3.98 
- 
1 (1.15) (1.72) (31.2) (36.0) 
E2G 0.319 0.0548 2.53 0.126 0.426 0.00798 1 
1.08 1.47 54.4 58.7 
- 
(1.08) (1.47) (54.4) (58.7) 
Atorvastatin 0.351 0.0319 0.734 0.0297 0.339 0.0161 
0.8 1.06 1.55 4.23 4.28 
9.0, 15h 
1 (1.07) (1.80) (22.1) (23.7) 
Pitavastatin 0.119 0.0239 1.3 0.0282 0.617 0.00702 
0.43 1.08 1.29 1.74 1.74 
4.6h 
1 (1.21) (2.07) (88.9) (108) 
Rosuvastatin 0.193 0.0312 1.64 0.0309 0.74 0.00227 
0.82 1.10 1.59 5.48 5.49 
7.1h 
1 (1.13) (1.82) (327) (371) 
a IC50 values estimated without preincubation. 
b IC50 values estimated after 30 min preincubation with CsA. 
c Calculated using Eq. 2, based on the data shown in Fig. 3. 
d Calculated using Eq. 8. 
e Calculated using replotting the data shown in Fig. 4 into sigma-minus plot in logarithmic scale, followed by linear regression analysis. 
f Calculated by Eq. 5 based on the data shown in Supplemental Table 1. 
g R0', R1', R2', and R3' values were calculated by assuming f value as unity.  




Pharmacokinetic parameters of preincubation-dependent OATP1B1 inhibitors 
Parameters 
Inhibitors 
CsA Regorafenib Nilotinib Pazopanib Asunaprevir 
Cmax (μmol/L) 0.95a,b 5.22g 1.66i 92.8k 0.078m 
ka (min-1) 0.0152c 0.1h 0.0123j 0.00968k 0.1h 
FaFg 1d 1d 0.30i 0.225k 0.19n 
Dose (μmol/kg) 2.4a 4.73g 10.8i 26.1k 3.82m 
RB 1.05e 0.629g 0.68i 0.63k 0.55n 
fu,p 0.107f 0.00188g 0.016i 0.00018l 0.003n 
Qh (L/h/70 kg) 97 
a Mück et al., 1999  
b Blood concentration 
c Kawai et al., 1998 
d Assumed to be unity 
e Zaghloul et al., 1987 
f In-house data estimated by equilibrium dialysis method 
g Stivarga (regorafenib) Tablets, FDA approval package, 2012 
h Assumed to be unity 
i Tasigna (nilotinib) Oral Capsules, FDA approval package, 2007 
j Li et al., 2015 
k Votrient (pazopanib hydrochloride) Tablets, FDA approval package, 2009 
l Taguchi et al., 2019 
m Eley et al., 2015 




Kinetic parameters for inhibition, inactivation, and recovery of OATP1B1 activity, and estimation of DDIs potential of preincubation-dependent inhibitors 
Inhibitors 
IC50 values (μM) kinactd kId kobse krecoveryf Iu,inlex,maxg R0 R1 R2 R3 Observed 
AUC ratio Pre(-)a Pre(+)c min-1 μM min-1 min-1 μM (R0') (R1') (R2') (R3')  
Regorafenib >10 0.403 0.365 3.63 0.00757 0.0378 0.0769 (1.01) (1.19) (1.21) (1.22)i NAj 
Nilotinib >10 0.235 0.411 2.05 0.0154 0.0627 0.0797 (1.01) (1.34) (1.25) (1.26)i NAj 
Pazopanib 1.42b 0.314b 0.856 0.525 0.0422 0.0416 0.0272 (1.02) (1.09)b (2.01) (2.05) 1.26k, 1.89l 










a IC50 values estimated without preincubation. 
b Cited from Taguchi et al., 2019. 
c The lowest IC50 values shown in Supplemental Table 2. 
d Calculated by Eq. 4 based on the data shown in Supplemental Fig. 2. 
e Calculated by Eq. 10.  
f Calculated by replotting the data shown in Supplemental Fig. 3 into sigma-minus plot in logarithmic scale, followed by linear regression analysis. 
g Calculated by Eq. 7 based on the data shown in Supplemental Table 1. 
h f = 0.82 (Rosuvastatin) 
i IC50,pre(-) is assumed to be 10 μM since inhibition did not reach 50% at maximum inhibitor concentration (10 μM). 
j Not applicable. 
k Hamberg et al., 2015. 
l Calculated based on AUC of SN-38 after administration of irinotecan (Bennouna et al., 2015). 





Effect of preincubation with regorafenib, nilotinib, pazopanib, and asunaprevir on OATP1B1-mediated uptake 
Preincubation period IC50 value (μM)a 
(min) Regorafenib Nilotinib Pazopanibb Asunaprevir 
0 >10 >10 1.42  0.23 0.170  0.074 
1 >10 3.98  1.50 0.594  0.030 0.176  0.041 
5 >10 6.88  1.56 0.314  0.028 0.138  0.040 
30 4.08  0.48 1.89  0.37 0.374  0.074 0.0349  0.0103 
60 0.403  0.234 0.235  0.169 0.530  0.022 0.0415  0.0170 
a IC50 values were estimated based on the data shown in Supplemental Fig. 1 by a nonlinear least-squares regression analysis (parameter estimate ± parameter 
S.D., n = 3-4). 





 OATP1B1 DDI  Iu,inlet,max Ki
OATP1B1
 
3 OATP1B1 CsA R1  AUC
 R2 R3 AUC Table 1  asunaprevir
Table 2  R2 R3  OATP1B1 DDI
 
 3 OATP1B1 CsA R2 R3 AUC  
DDI Atorvastatin OATPs BCRP P-gp CYP3A  pitavastatin
OATP1B1 rosuvastatin OATPs BCRP P-gp OATP1B1
 
Prueksaritanont et al., 2014; Yoshida et al., 2012  CsA OATP1B1
 OATP1B3 CYP3A4 BCRP Duan et al., 2017
 atorvastatin pitavastatin rosuvastatin CsA  OATP1B1
DDI
 DDI  OATP1B1 f R1 
R2 R3 f  f 3
  DDI
f 1 R’ R2’ R3’ AUC
DDI  Table 1





 regorafeni nilotinib OATP1B1
Table 4  OATP1B1  
 regorafenib nilotinib
R’ 1.2–1.3  OATP1B1
DDI  pazopanib R2’ R3’ 2
DDI  3 pazopanib
OATP1B1 AUC  pazopanib
OATP1B1 DDI  
 
Izumi  1 CsA IC50 OATP1B1
6 Izumi et al., 2015  
OATP1B1 kinact kI krecovery
 3.4 5.1 7.1  




E2G R2 R3 E1S R2 R3 Table 1  E2G
 
 Km  IC50 Ki
R0 R1  /
 CsA IC50






 OATP1B1  DDI
DDI  
OATP1B1  OATP1B1 DDI
DDI  OATP1B1 DDI










DDI / OATP DDI




2 CsA  
DDI AUC DDI AUC
In vitro AUC DDI AUC
 CsA CsA Oatp
 
DDI DDI  
OATP DDI DDI
 
3 OATP1B1  
OATP1B1 DDI pazopanib OATP1B1
DDI Pazopanib CsA
OATP1B1  OATP1B1 Km Vmax
 pazopanib OATP1B1
CsA IC50
R1 1.09  pazopanib OATP1B1 DDI




4  OATP1B1 DDI
DDI  OATP1B1 DDI
 DDI
 OATP1B1  OATP1B1 DDI
 DDI AUC  
DDI  OATP1B1 100%











Pravastatin ABT  Tokyo Chemical Industries Tokyo, Japan Rifampicin
 Sigma-Aldrich St. Louis, MO CsA midazolam Atorvastatin calcium 
trihydrate  FUJIFILM Wako Pure Chemical Corporation Tokyo, Japan CsA
M1  Toronto Research Chemicals North York, Canada
Pazopanib  Synkinase Pty Ltd Victoria, Australia Pitavastatin calcium  
Avachem Scientific San Antonio, TX Rosuvastatin calcium AK Scientific Union 
City, CA Pazopanib  Synkinase Pty Ltd. Victoria, Australia
Asunaprevir  Santa Cruz Biotechnology Dallas, TX Nilotinib  ChemScene 
LLC Monmouth Junction, NJ Regorafenib  Toronto Research Chemicals North 
York, ON [3H]Estrone 3-sulfate E1S 51.8 Ci/mmol  PerkinElmer Waltham, 
MA [3H]Estradiol-17β-glucuronide (E2G)  American Radiolabeled Chemicals
St Louis, MO PerkinElmer Waltham, MA 3
Lot No. Rs702 from 8-weeks-old male Sprague-Dawley rats  
ThermoFisher Scientific St. Louis, MO Lot No. Hu8239 from 







6 Sprague-Dawley Kanagawa, Japan
 
 66 




DMSO  Kolliphor ELP 2 : 2.5 : 2.5 : 93
0.1 0.5 1 3 5 mg/kg CsA 10 mg/kg rifampicin
 0.5% M.C. 30 mg/kg pravastatin 10 mg/kg
midazolam CsA Oatp
 5 mg/kg CsA 1  3 7
 30 mg/kg pravastatin CsA
Oatp  P450 ABT
20 mg/kg
16  0.5 mg/kg CsA
1  
30 mg/kg pravastatin Rifampicin DDI
 DMSO β
5 : 13 : 82 10 mg/kg 25 mg/kg rifampicin
5
 30 mg/kg pravastatin 10 mg/kg midazolam
 pravastatin 5 15 30  1 2 4 8
4°C 14,000×g 10  






 HEK293/OATP1B1 HEK293 OATP1B1 FLAG
OATP1B1 HE293/OATP1B1 L-
glutamine phenol red  10%  /
1 mg/mL G418 Dulbecco’s modified Eagle’s medium DMEM, high glucose  FUJIFILM 
Wako Pure Chemical 37°C  5% CO2  
 
6-5. HEK293/OATP1B1  
HEK293/OATP1B1 poly-D-lysine 4 well ThermoFisher Scientific
24 well Becton Dickinson, Franklin Lakes, NJ 1.0 105 cells/well
2  5 μL 500 mM 5 mM  
Pre+Co
 37°C transport buffer 125 mM NaCl, 4.8 mM KCl, 
1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 35 mM HEPES, and 5.6 mM D-glucose, pH 7.4
2  transport buffer 5  
1% DMSO transport buffer  37°C 0–60
  transport buffer
 transport buffer  
Coincubation Co transport buffer HEK293/OATP1B1
30  transport buffer  
Pre  
transport buffer HEK293/OATP1B1 30  37°C transport 
buffer  transport buffer  
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OATP1B1  HEK293/OATP1B1 30 CsA
60 asunaprevir, nilotinib, regorafenib pazopanib  
 37°C
transport buffer  transport buffer  
OATP1B1  
transport buffer 30  37°C transport buffer
 [3H]E1S E1S HEK293/OATP1B1  
OATP1B1 pazopanib CsA
 pazopanib CsA transport buffer 30
 37°C transport buffer  transport buffer
HEK293/OATP1B1  OATP1B1
 HEK293/OATP1B1 CsA; 0.05–0.5 μM, asunaprevir; 0.05–1 μM, nilotinib; 
0.2–5 μM; regorafenib; 1–10 μM, pazopanib; 0.1–2 μM transport buffer
CsA; 20 sec-3 min, asunaprevir; 1–5 min, nilotinib; 1–5 min, 
regorafenib; 5–30 min, pazopanib; 0–2 min  
37℃ transport buffer 1  transport buffer
 0.5 [3H]E1S [3H]E2G 1 atorvastatin pitavastatin
rosuvastatin   transport buffer 2
 0.2 mL 0.2 N NaOH  HCl  
Tricarb 4910TR, 
PerkinElmer; LSC-6100, Aloka Tokyo, Japan





6-6. pravastatin  
37°C  thawing medium ThermoFisher Scientific
  50×g 5  Krebs–
Henseleit KH  buffer 118 mM NaCl, 23.8 mM NaHCO3, 4.8 mM KCl, 1.0 mM KH2PO4, 1.2 
mM MgSO4, 12.5 mM HEPES, 5.0 mM D-glucose, and 1.5 mM CaCl2, pH 7.4  4°C 
50×g 5  KH buffer
 Takeuchi et al., 2014
37°C 5  37°C 2 
μM pravastatin CsA rifampicin DMSO KH buffer
 Rifampicin KH buffer 0.01–1000 μM
CsA KH buffer 0.01–10 μM  0.1–100 μM
DMSO 1% v/v 3  
200 μL 100 μL  1.035 5M 50 
μL   
100 μL  
 
 pravastatin pravastatin CsA




37°C  thawing medium ThermoFisher Scientific
  100 g 10  seeding medium 0.8 106 viable cells/mL
 collagen I 24 well 4
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 37°C KH buffer 2  pazopanib CsA
KH buffer 30 30  37°C KH buffer 1  
[3H]E1S KH buffer 30 30  




CsA rifampicin pazopanib  
5 nm 14,000 Da
1  200 400 750 μL
0.1 M pH7.4  37°C 20
  LC-MS LC-MS/MS
 
 
6-9. LC-MS/MS  
6-9-1. TSQ Quantum Ultra LC-MS/MS pravastatin rifampicin midazolam
 
(1)   HTC PAL LC  
(CTC Analytics) 
(2)  Accela   (Thermo Fisher Scientific) 
(3)   TSQ Quantum Ultra (Thermo Fisher Scientific) 
HPLC  
 YMC-Triart C18 5 μm, 2.0 mm ID×50 mm, pore 12 nm  
A  0.1 vol%  
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B   
40°C 
 15 μL 
 
  A B 
min μL/min % % 
0.00  800  95  5  
0.50  800  95  5  
0.51  800  10  90  
0.60  800  10 90  
0.61  300  10  90  
3.00 300  10 90  
3.01  800  0  100  
5.00  800  0  100  
5.01 800  95  5  
6.00  800  95  5  
 
MS  
Ionization Method: Electrospray Ionization (ESI) 
MS Acquire Time: 6.0 min 
Q2 Collision Gas Pressure:1.5 mTorr 
Spray Voltage:  4000 V 
Sheath Gas Pressure: 30 Arb 
Auxiliary Gas Pressure: 35 Arb 
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Capillary Temperature: 300°C 
Scan Width:  ±0.50 amu 
Scan Time:  0.050 s 
Q1 Peak Width:  0.70 FWHM 
Q3 Peak Width:  0.70 FWHM 
Compound 
Precursor ion Product ion 
(m/z) (m/z) 
Pravastatin 423.200  321.200  
Rifampicin 821.400  397.200  
Midazolam 326.100  291.100  
Ketoconazole 531.200  243.900  
 
6-9-2. TSQ Quantum Vantage LC-MS/MS CsA CsA M1 atorvastatin, pitavastatin
fluvastatin  
(1)   NANOSPACE SI-2 3133   
(2)  NANOSPACE SI-2 3101  
NANOSPACE NASCA2 5200  
(3)   TSQ QUANTUM Vantage 
Thermo Fisher Scientific 
HPLC  
 Capcell Pak C18 3 μm, 1.5 mm ID×35 mm, pore 12 nm  
A  1 mM  




 10 μL 
  A B 
min μL/min % % 
Init 400  85 15 
0.60 400  85 15 
0.61 400  5 95 
2.80 400  5 95 
2.81 400  0 100 
3.70 400  0 100 
3.71 600  0 100 
4.60 600  0 100 
4.61 400  85 15 
7.50 400  85 15 
 
HPLC  
 YMC-Triart C18 5 μm, 2.0 mm ID×50 mm   
A  0.1%  
B   
40°C 
 10 μL 
  A B 
min μL/min % % 
Init 400  85 15 
0.60 400  85 15 
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0.61 400  5 95 
2.80 400  5 95 
2.81 400  0 100 
3.70 400  0 100 
3.71 600  0 100 
4.60 600  0 100 
4.61 400  85 15 
7.50 400  85 15 
MS  
Ionization Method ESI) 
MS Acquire Time 8.0 min 
Q2 Collision Gas Pressure 1.5 mTorr 
Spray Voltage  3500 V 
Sheath Gas Pressure 40 Arb 
Auxiliary Gas Pressure 25 Arb 
Capillary Temperature 235°C (CsA M1) 
330°C(atorvastatin, pitavastatin fluvastatin) 
Scan Width  ± 0.50 amu 
Scan Time  0.20 s 
Q1 Peak Width  0.70 FWHM 
Q3 Peak Width  0.70 FWHM 
Compound 
Precursor ion Product ion 
Ion mode 
(m/z) (m/z) 
Atorvastatin 480.200  418.200 Positive 
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Pitavastatin 422.300 274.100  Negative 
Rosuvastatin 480.200 418.200 Negative 
CsA 1202.9 425.300 Positive 
M1 1219.0 425.300 Positive 
Ketoconazole 531.200  243.900  Positive 
 
6-9-3. Q ExactiveTM LC-MS  
(1)   HTC PAL LC  
(CTC Analytics) 
(2)  Accela   (Thermo Fisher Scientific) 
(3)   Q Exctive  (Thermo Fisher Scientific) 
HPLC  
 CAPCELL PAK C18 ACR 3 µm 1.5 mm I.D. × 35 mm  
A  0.1 vol%  
B   
40°C 










Init 800 95.0 5.0 
0.50 800 95.0 5.0 
0.51 800 10.0 90.0 
0.80 800 10.0 90.0 
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0.81 300 10.0 90.0 
3.00 300 10.0 90.0 
3.01 800 0.0 100.0 
5.00 800 0.0 100.0 
5.01 800 95.0 5.0 
6.00 800 95.0 5.0 
 
MS  
Ionization Method: ESI 
MS Run Time: 3.00 min 
Spray Voltage:  3500 V 
Spray Current:  0 µA 
Sheath Gas flow rate: 40 Arb 
Aux Gas flow rate: 10 Arb 
Capillary Temperature: 330°C 
Vaporizer Temperature: 280°C 
S-lens RF level:  50.0 
Scan range:  150.0 to 1000.0 m/z 
Resolution:  35000 
Scan Events:  Targeted-SIM Selected-Ion Monitoring) 
Isolation windows: 4.0 m/z 
Pazopanib:  m/z 438.1707 
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6-10-2. in vivo Ki  
(CL/Finhibitor)/(CL/Fcontrol) = α [Ki,in vivoγ / (Iγ + Ki,in vivoγ)] + (1-α) 1  
CL/Fcontrol CsA pravastatin  
CL/Finhibitor CsA pravastatin  
α  
γ  
I CsA pravastatin 5  
 
6-10-3. in vitro IC50  
















6-10-5. KI kinact  
kobs,app = kinact I / (KI + I)     4  






MULTI program Yamaoka et al., 1981 Damping Gauss-Newton
 
 
6-11. R  
 DDI
R0 R1  OATP1B1
DDI R0’ R1’  
R0 or R1 = 1 / ((1 / R1’ ) • f + (1 - f))    5  
R0’ or R1’ = 1 + Iu,inlet,max / Ki     6  
Iu,inlet,max  
Ki  
f OATP1B1  
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in vitro  Km
 Ki in vitro IC50 Iu,inlet,max  
Ito et al., 1998  







RB /  
 
 OATP1B1 DDI R2 R2’  
R2 = 1 / ((1 / R2’) • f + (1 - f))     8  
R2’ = (kobs + krecovery) / krecovery     9  
kobs  
krecovery  
krecovery OATP1B1  OATP1B1
 
kobs  
kobs = kinact × Iu,inlet,max / (KI + Iu,inlet,max)    10  
 




R3 = 1 / (Ah Bh f + (1-f))     11  
R3’ = 1 / (Ah×Bh) 
Ah OATP1B1  
Bh OATP1B1  
Ah Bh  
Ah = 1 / (1 + Iu,inlet,max / IC50,pre(-))    12  




Student t 2 P 0.05
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